Loading…
World's largest biologics contract manufacturer, producing biotech drugs and antibody-drug conjugates for global pharma clients.
World's largest biologics contract manufacturer, producing biotech drugs and antibody-drug conjugates for global pharma clients.
Customers sign multi-year contracts that reserve manufacturing capacity and pay per batch made, with development work up front as a way of locking in later production. Samsung C&T, the group's de facto holding company, is the largest shareholder. Growth has come from adding large plants in Songdo, South Korea, in stages, each filled by contracts agreed years ahead.
In one line: Korea's Lonza/Catalent — a pure-play biologics contract manufacturer..
Moat: wide (scale, regulatory licence, installed base). World's largest biologics manufacturing capacity; FDA/EMA-approved plants are costly to replicate or switch away from.
Headquarters: Incheon, South Korea · Founded: 2011 · Employees: 5,455
Size Samsung Biologics (207940.KS) is a South Korea Health Care company (Biotechnology) with a market value of $53.7B, the 5th largest of 495 South Korea companies the cockpit tracks. Shares closed at ₩1,516,000 on 6 Nov 2026.
Performance Over six months the shares gained 3.1%, against +33.3% for the median peer and -24.5% for the South Korea market (cap-weighted) — 3rd lowest of 15 in its peer set.
Growth Revenue fell 20.5% over the last twelve months (peer median +11.6%); the operating margin is 43.4% (peer median 25.1%).
Valuation It trades at 38.7× forward earnings against a peer median of 22.4× (2nd most expensive of 10).
Price implies For today's price to make sense, revenue must grow about 10% a year for seven years (Req g). Recent delivered growth is +31%, so the hurdle is -22 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 13.3 points above its cost of capital (5.5% WACC).
Next results Next results expected around 27 Jan 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩4.38T | ₩4.56T | ₩3.50T | ₩3.69T | ₩3.00T |
| Revenue growth | — | +30% | -5% | +23% | — |
| Gross profit | n/a | ₩2.48T | ₩1.68T | ₩1.77T | ₩1.44T |
| EBITDA | n/a | ₩2.70T | ₩1.92T | ₩1.60T | ₩1.29T |
| Net income | ₩1.80T | ₩1.78T | ₩1.08T | ₩858B | ₩798B |
| Free cash flow | n/a | ₩856B | ₩356B | ₩671B | -₩3.79B |
| Capital expenditure | n/a | ₩1.48T | ₩1.38T | ₩1.11T | ₩1.01T |
| Total debt | n/a | ₩927B | ₩1.49T | ₩1.91T | ₩2.51T |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Samsung Biologics 207940.KS | $53.7B | +3% | -20% | 43% | 38.7× | 9.6% |
| Lonza LONN.SW | $55.4B | +39% | -11% | 25% | 36.1× | 15.0% |
| Wuxi Bio 2269.HK | $25.0B | +43% | +22% | 32% | 28.7× | 21.8% |
| Thermo Fisher Scientific TMO | $257B | +50% | +8% | 19% | 25.8× | 20.9% |
| Celltrion 068270.KS | $34.3B | +10% | +40% | 32% | 34.1× | 8.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 207940.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +18.7% | +12.3% | 2nd highest of 15 |
| 6-month return | +3.1% | +33.3% | 3rd lowest of 15 |
| Distance from 52-week high | -23.7% | -11.6% | 4th lowest of 15 |
| Revenue growth (TTM) | -20.5% | +11.6% | 2nd lowest of 15 |
| Operating margin | 43.4% | 25.1% | 2nd highest of 15 |
| Forward P/E | 38.7× | 22.4× | 2nd most expensive of 10 |
| Growth the price implies (Req g, 7 yrs) | 9.6% | 8.3% | 6th most demanding of 12 |
| Growth delivered (Del g) | +31.4% | +17.6% | 3rd highest of 12 |
| Hurdle (Req g minus delivered) | -21.8 pp | -8.4 pp | 4th least demanding of 12 |
| ROIC minus cost of capital | +13.3 pp | +2.8 pp | 5th highest of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Samsung Biologics 207940.KS | South Korea | $53.7B | +3% | -20% | 43% | 38.7× | 9.6% | +31.4% |
| Lonza LONN.SW | Switzerland | $55.4B | +39% | -11% | 25% | 36.1× | 15.0% | +7.7% |
| argenx SE Sponsored ADR ARGX | United States | $57.5B | +19% | +71% | 29% | n/a | 10.9% | +151.4% |
| Iqvia IQV | United States | $44.8B | +52% | +9% | 14% | 19.7× | 17.3% | +7.5% |
| Natera NTRA | United States | $44.8B | +60% | +38% | -11% | n/a | n/a | n/a |
| CSL CSL.AX | Australia | $67.2B | +105% | -2% | 26% | 22.4× | 7.1% | +11.0% |
| Celltrion 068270.KS | South Korea | $34.3B | +10% | +40% | 32% | 34.1× | 8.3% | +17.6% |
| Genmab A/S GMAB.CO | Denmark | $32.1B | +115% | +14% | 32% | 44.8× | 11.6% | +19.5% |
| Moderna MRNA | United States | $101B | +43% | -28% | -149% | n/a | n/a | n/a |
| Wuxi Bio 2269.HK | Hong Kong | $25.0B | +43% | +22% | 32% | 28.7× | 21.8% | +30.2% |
| United Therapeutics UTHR | United States | $24.1B | -1% | +2% | 44% | 22.0× | -0.4% | +16.5% |
| BioNTech SE Sponsored ADR BNTX | United States | $22.8B | -7% | -1% | -38% | n/a | 5.7% | +42.6% |
| Neurocrine Biosciences NBIX | United States | $16.7B | +8% | +38% | 25% | 18.2× | -1.7% | +22.3% |
| BridgeBio Pharma BBIO | United States | $14.5B | +10% | +167% | -37% | n/a | n/a | n/a |
| Gilead Sciences GILD | United States | $207B | +28% | +7% | 38% | 19.3× | -2.9% | +3.6% |